Home・Список акций・Genmab A-S

Genmab A-S

Закрыт

1,794.5 0.11

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1784.5

Макс.

1835.5

Ключевые показатели
By Trading Economics
Доход	21M 52M
Продажи	-184M 881M
P/E Средняя по отрасли	21.339 56.269
Прибыль на акцию	8.48
Рентабельность продаж	5.915
Сотрудники	3,088
EBITDA	-30M 215M

Рекомендации
By TipRanks
Рекомендации	Нейтрально
Прогноз на 12 месяцев	-1.49% downside

Дивиденды
By Acuity
Следующий отчет о доходах	6 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	8.4B 113B
Предыдущая цена открытия	1794.39
Предыдущая цена закрытия	1794.5

Genmab A-S График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

30 июн. 2026 г., 23:56 UTC

Ulta Beauty shares rose in after-market trading, though they remain below the 20-day moving average and near the lower end of their one-month range.

30 июн. 2026 г., 23:56 UTC

Correlated Moves

After-market trading for the iShares Core U.S. Aggregate Bond ETF is roughly flat, reflecting routine performance amid slight gains in the US 2Y Treasury Bond.

30 июн. 2026 г., 23:52 UTC

European equity indices rise as Germany's inflation falls below expectations, easing ECB tightening concerns, while Bitcoin declines amid market volatility.

30 июн. 2026 г., 23:52 UTC

Global markets show mixed performance as European indices rise on tech optimism while U.S. stocks decline amid volatility, with the dollar strengthening against the yen and Bitcoin falling due to regulatory concerns.

30 июн. 2026 г., 23:52 UTC

U.S. equity indices decline as tech stocks sell off, while European markets rise on positive economic data; dollar strengthens amid Fed rate hike expectations and Bitcoin drops 2.8%.

30 июн. 2026 г., 23:52 UTC

Mixed Asia equity markets as Japan's optimism contrasts with U.S. profit-taking; Bitcoin declines amid shifting investor focus ahead of key U.S. employment data.

30 июн. 2026 г., 23:52 UTC

Bank of Japan to release Q2 Tankan Index on June 30, with market expectations set at a stable 16.0 amid ongoing optimism in manufacturing sector.

30 июн. 2026 г., 23:52 UTC

South Korea's Exports Expected to Surge Again Ahead of July 1 Release Amid Strong Semiconductor Demand and Positive Market Sentiment.

30 июн. 2026 г., 23:52 UTC

South Korea's S&P Global Manufacturing PMI set for July 1, with positive trends expected amid regional growth signals and inflation concerns.

30 июн. 2026 г., 23:52 UTC

ISM Manufacturing Employment Report Set for July 1: Market Eyes Mixed Economic Signals and Job Growth Ahead of Potential Fed Rate Hikes.

30 июн. 2026 г., 23:52 UTC

Australia's Balance of Trade data set for July 2, 2026, anticipates a AUD 2.3 billion surplus amid mixed stock market sentiment and geopolitical concerns.

30 июн. 2026 г., 23:52 UTC

ISM Manufacturing PMI for June 2026 set to release on July 1, forecasted at 54.0 amid cautious optimism and geopolitical tensions impacting market stability.

30 июн. 2026 г., 23:52 UTC

Brazil's BCB Focus Market Readout on July 6, 2026, may signal interest rate adjustments amid mixed investor sentiment influenced by inflation and global market pressures.

30 июн. 2026 г., 23:52 UTC

Brazil's Industrial Production Expected to Continue Growth Trend Ahead of July 2 Release Amid Record Oil Output from Petrobras

30 июн. 2026 г., 23:52 UTC

Canada's Manufacturing PMI Release on July 2 Expected to Reflect Economic Resilience Amid Mixed Global Signals and Geopolitical Pressures.

30 июн. 2026 г., 23:52 UTC

ECB Forum on Central Banking Set for July 2026 Amid Cautious Market Sentiment and Potential Changes to Interest Rates.

30 июн. 2026 г., 23:52 UTC

Japan's Current Account Data Release on July 7, 2026, Expected to Reflect Economic Trends Amidst Cautious Investor Optimism.

30 июн. 2026 г., 23:51 UTC

Correlated Moves

ETF Constituents

Vanguard FTSE Europe ETF is lower in after-market hours, influenced by mixed returns from holdings like BCS and NOK, as well as broader market sentiment.

30 июн. 2026 г., 23:51 UTC

ETF Constituents

Vanguard Small-Cap ETF declines after hours, impacted by significant losses in holdings like SSTK, BLDR, and TOL. Trading activity remains weak.

30 июн. 2026 г., 23:51 UTC

ETF Constituents

VanEck Gold Miners ETF declines in after-market trading, following three consecutive lower daily closes. KGC, AEM, and NEM all recorded negative returns.

30 июн. 2026 г., 23:51 UTC

No specific news was identified for Biomarin Pharmaceutical Inc. After-market trading has been routine, with shares showing little change since Tuesday's close.

30 июн. 2026 г., 23:51 UTC

Texas Instruments Inc. shares are trading higher in after-market hours, reflecting broader positive momentum in equity indices amid optimism around economic data and AI investments.

30 июн. 2026 г., 23:46 UTC

NetEase Inc. shares are higher in after-market trading, reflecting unusual strength following three consecutive sessions of gains amid a positive trend in European equities.

30 июн. 2026 г., 23:46 UTC

Lululemon Athletica Inc shares are lower in after-market hours, remaining near the lower end of their one-month range and below the 20-day moving average.

30 июн. 2026 г., 23:46 UTC

ETF Constituents

iShares MSCI South Korea ETF declines after market close, influenced by mixed global equity performance. LG Display saw a positive return, while SK Telecom had minimal impact.

30 июн. 2026 г., 23:46 UTC

ETF Constituents

iShares China Large-Cap ETF advances in after-market trading, influenced by JD's negative contribution. FXI remains near the lower end of its one-month range.

30 июн. 2026 г., 23:42 UTC

Australia's Ai Group Industry Index plunges to -30.0, signaling severe industrial contraction amid mixed economic signals and persistent challenges.

30 июн. 2026 г., 23:42 UTC

MBA 30-Year Mortgage Rate Release on July 1 Expected to Show Stability Amid High Borrowing Costs and Mixed Consumer Confidence in Housing Market

30 июн. 2026 г., 23:42 UTC

Mexican Business Confidence Remains Low at 47.5 Points Ahead of Key EMOE Report Amid Regulatory Changes and Economic Uncertainties

30 июн. 2026 г., 23:42 UTC

Australia's Building Permits Expected to Rise 0.01% Amid Cautious Economic Sentiment and Mixed Market Indicators

Сравнение c конкурентами

Изменение цены

Genmab A-S Прогноз

Целевая цена

By TipRanks

-1.49% падение

Прогноз на 12 месяцев

Средняя 2,493.35 DKK -1.49%

Максимум 3,320 DKK

Минимум 308.417 DKK

Основано на мнении 7 аналитиков Wall Street, спрогнозировавших целевые цены для Genmab A-S на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

7 ratings

Покупка

Удержание

Продажа

Основано на мнении 7 аналитиков, присваивавших рейтинги акциям Genmab A-S – Данные за последние 3 месяца.

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.